Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents
Carolina Garrido, … , Matthew S. Kelly, Genevieve G. Fouda
Carolina Garrido, … , Matthew S. Kelly, Genevieve G. Fouda
Published July 6, 2021
Citation Information: JCI Insight. 2021;6(17):e150909. https://doi.org/10.1172/jci.insight.150909.
View: Text | PDF
Research Article Immunology Infectious disease

Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents

  • Text
  • PDF
Abstract

As SARS-CoV-2 continues to spread globally, questions have emerged regarding the strength and durability of immune responses in specific populations. In this study, we evaluated humoral immune responses in 69 children and adolescents with asymptomatic or mild symptomatic SARS-CoV-2 infection. We detected robust IgM, IgG, and IgA antibody responses to a broad array of SARS-CoV-2 antigens at the time of acute infection and 2 and 4 months after acute infection in all participants. Notably, these antibody responses were associated with virus-neutralizing activity that was still detectable 4 months after acute infection in 94% of children. Moreover, antibody responses and neutralizing activity in sera from children and adolescents were comparable or superior to those observed in sera from 24 adults with mild symptomatic infection. Taken together, these findings indicate that children and adolescents with mild or asymptomatic SARS-CoV-2 infection generate robust and durable humoral immune responses that can likely contribute to protection from reinfection.

Authors

Carolina Garrido, Jillian H. Hurst, Cynthia G. Lorang, Jhoanna N. Aquino, Javier Rodriguez, Trevor S. Pfeiffer, Tulika Singh, Eleanor C. Semmes, Debra J. Lugo, Alexandre T. Rotta, Nicholas A. Turner, Thomas W. Burke, Micah T. McClain, Elizabeth A. Petzold, Sallie R. Permar, M. Anthony Moody, Christopher W. Woods, Matthew S. Kelly, Genevieve G. Fouda

×

Figure 1

SARS-CoV-2–specific binding antibodies in children and adolescents after acute infection.

Options: View larger image (or click on image) Download as PowerPoint
SARS-CoV-2–specific binding antibodies in children and adolescents after...
Specific binding to SARS-CoV-2 antigens was measured by Luminex-based multiplex assays for IgM (A), IgG (B), and IgA (C) antibodies against the whole spike, subunit 1 (S1), receptor-binding domain (RBD), N-terminal domain (NTD), subunit 2 (S2), nucleocapsid (NC), and membrane (M) proteins. Binding is expressed as mean fluorescence intensity (MFI) of sera at the time of acute infection (M0) and 2 months (M2) and 4 months (M4) after acute infection. Heatmaps show binding to all analyzed SARS-CoV-2 antigens, with darker colors corresponding to higher binding. Line graphs depict RBD-, NC-, and whole spike–specific binding of sera from individual participants (light blue lines) and the geometric mean of all individuals (thick blue lines). Dotted lines indicate assay positivity thresholds and were calculated as the mean MFI plus 3 standard deviations using sera from 10 SARS-CoV-2–uninfected individuals. Comparisons of samples from individuals across time points were made using Wilcoxon signed-rank tests. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts